DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Ocular Pain - Pipeline Review, H2 2016" report to their offering.
'Ocular Pain - Pipeline Review, H2 2016'; Ocular Pain pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.
Furthermore, the publisher says; Ocular Pain Ocular pain occurs on the surface of eye. Ocular pain is usually caused by irritation from a foreign object, infection, or trauma. Symptoms include light sensitivity, discharge, which can be clear, or thick and colored (pus), decreased vision, headache and conjunctivitis (red itchy eyes). Treatment includes antibiotics, antihistamines and corticosteroids
'Ocular Pain - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects. Currently, The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 4, 3 and 6 respectively.
Key Topics Covered:
- Introduction
- Ocular pain Overview
- Therapeutics Development
- Pipeline Products for Ocular pain - Overview
- Pipeline Products for Ocular pain - Comparative Analysis
- Ocular pain - Therapeutics under Development by Companies
- Ocular pain - Therapeutics under Investigation by Universities/Institutes
- Ocular pain Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Ocular pain - Products under Development by Companies
- Ocular pain - Products under Investigation by Universities/Institutes
- Ocular pain - Companies Involved in Therapeutics Development
- D. Western Therapeutics Institute, Inc.
- InSite Vision Incorporated
- Kala Pharmaceuticals, Inc.
- Ocular Therapeutix, Inc.
- Reata Pharmaceuticals, Inc.
-
Sylentis S.A.U.
For more information about this report visit http://www.researchandmarkets.com/research/wglrjx/ocular_pain
